NATALEE: Adjuvant Ribociclib Plus NSAI Improves Long-Term Survival in HR+/HER2- Early Breast Cancer

CancerTherapyAdvisor· @CancerTherAdvsr · X·2026-10-24 04:09· 1 day agoScore70

Body

Ribociclib plus NSAI therapy was associated with significant improvement in OS, at a rate of 91.9% at 6 years compared to 89.7% with NSAI alone #ESMO26

🔗 https://bit.ly/4jySLyB

92 views · 0 likes · 0 reposts · 0 replies

Conference abstracts

LBA25matched by Proffered paper 1: Breast cancer, early and advanced stage

Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes

https://esmocongress.esmo.org

Source: CancerTherapyAdvisor · x.com